Today, the SVP & Pres, Eur, Mid-East, Afr of Boston Scientific Corp (BSX), Thepaut Eric Francis Yves, sold shares of BSX for $838.2K.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $2.49 billion and quarterly net profit of $424 million. In comparison, last year the company earned revenue of $2.38 billion and had a net profit of $298 million. BSX’s market cap is $52.94B and the company has a P/E ratio of 30.03. Currently, Boston Scientific Corp has an average volume of 6.96M.
Based on 10 analyst ratings, the analyst consensus is Strong Buy with an average price target of $43.25, reflecting a 12.5% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
